



Outcomes of cardiac surgery in Jehovah's Witness
patients




Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Chambault, A-L, Brown, LJ, Mellor, S & Harky, A 2020, 'Outcomes of cardiac surgery in Jehovah's Witness
patients: A review', Perfusion, pp. 267659120980375. https://doi.org/10.1177/0267659120980375
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.




© The Author(s) 2020
Article reuse guidelines: 
sagepub.com/journals-permissions
DOI: 10.1 77/0267 591209803
journals.sagepub.com/home/prf
Background
According to the latest figures from 2019, there are cur-
rently over 8 million Jehovah’s Witnesses (hereafter 
referred to as Witness/Witnesses) worldwide, spread 
across 240 countries.1 Whilst only equating to 0.1% of the 
world’s population, this unique sub-set of patients pro-
vides a distinctive challenge to medical professionals, due 
to their firmly held beliefs regarding blood transfusion 
and the use of blood products.2,3 The basic principle of 
these beliefs is the refusal of both blood transfusion and 
blood products due to interpretations made from the 
Bible, Genesis 9:4 and Acts 15:28–29.2,4 The abridged 
quote from the Acts reads that individuals must ‘abstain. . .
from blood’, and is just one quote which helps to formulate 
Witnesses stance on blood transfusions.2,5 These interpre-
tations of the Bible were first formulated by a group of 
Bible students in Pennsylvania, and through the dissemi-
nation of their work, the Witness following has grown 
substantially.1,6 The community now has its own govern-
ing body, as well as ‘The Watchtower Bible and Tract 
Society’, which aims to promote the societies views 
through use of education.7–10 Further to this, within the 
UK there are Hospital Liaison Committees for Jehovah’s 
Witnesses, which can provide support and advice to med-
ical professionals.11 This is particularly important for clini-
cians to consider, as prospective Witness patients present a 
complicated array of social, legal and ethical challenges.12 
This is especially true within the field of cardiac surgery 
and hence needs careful consideration.
A comprehensive literature search was performed 
between the years 2010 and 2020 in PubMed, Scopus, 
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Objective: To review current literature evidence on outcomes of cardiac surgery in Jehovah’s Witness patients.
Methods: A comprehensive electronic literature search was done from 2010 to 20th August 2020 identifying articles 
that discussed optimisation/outcomes of cardiac surgery in Jehovah’s Witness either as a solo cohort or as comparative 
to non-Jehovah’s Witnesses. No limit was placed on place of publication and the evidence has been summarised in a 
narrative manner within the manuscript.
Results: The outcomes of cardiac surgery in Jehovah’s Witness patients has been described, and also compared, to non-
Witness patients within a number of case reports, case series and comparative cohort studies. Many of these studies 
note no significant differences between outcomes of the two groups for a number of variables, including mortality. Pre-, 
intra and post-operative optimisation of the patients by a multidisciplinary team is important to achieve good outcomes.
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Google Scholar, and Embase. Key search terms included 
‘Jehovah’s Witness’, ‘Cardiac surgery’ and corresponding 
synonyms for outcomes. Non-English papers were 
excluded. Figure 1 shows the number of studies screened 
and included. This review examines pre-published data 
and therefore no human ethics or informed patient con-
sent was required.
Cardiac surgery and Jehovah’s 
Witness patients
Witness patients undergoing cardiac surgery is not 
without risk, primarily due to this surgery carrying an 
increased association with bleeding and the inability to 
transfuse blood products. In 1964, open heart surgery 
using cardiopulmonary bypass (CPB) on Witnesses was 
first described, made possible by the development of 
bypass techniques.14 Witnesses are often not considered 
for cardiac surgery due to the increased risk of morbid-
ity and mortality, with early research demonstrating a 
mortality rate of 7%–10%.15 This perceived risk is 
affected by the population being referred for cardiac 
surgery; at later stages in life, with multiple comorbidi-
ties, and often the use of new anticoagulants.4 As 
research has evolved, there has been a decrease in 
mortality rates demonstrated by a range of larger 
studies;16,17 whether this is due to improvements in 
blood management strategy, technology advances, or 
careful patient selection is unclear. The majority of 
Figure 1. Number of studies screened and included (based on the PRISMA flow diagram).13
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these findings are limited to adults, however research 
has now been extended to include infants and children, 
highlighting similar results and emphasising the need 
for more liberal, instead of restrictive, transfusion strat-
egy.18,19 Greater complications arise when the size of the 
patient is taken into consideration,19 largely due to the 
resultant increase in haemodilution from CPB prime 
volume to the circulating blood volume of neonates and 
infants.18,20 However, Olshove et al.21 demonstrated that 
bloodless cardiac surgery is feasible for this population 
if a comprehensive blood conservation program is 
adopted. This can be achieved through careful discus-
sion and a thorough understanding of the patients’ 
beliefs at the pre-operative stage. This is particularly 
important to comprehend because not all Witness 
patients hold identical beliefs and the exact level of 
acceptance of blood product usage lies with each indi-
vidual, as discussed below.
Patient beliefs and considerations
The Bible teachings of Charles Taze Russell are the 
basis of the beliefs held by Witnesses, which state the 
transfusion of allogenic whole blood and primary 
blood components (platelets, white cells, plasma or 
packed red cells) are unacceptable.22,23 Witnesses also 
decline autologous transfusion, as blood is consid-
ered unclean once it has left the body, and blood sam-
pling for use in cross-matching.23 The use of a number 
of related treatments is a matter of personal decision 
for the individual. The derivatives of primary blood 
products include albumin, coagulation factors, inter-
ferons, haemoglobin and globulins/immunoglobu-
lins. Autologous procedures, such as haemodilution, 
cardiac bypass and cell salvage, may also be deemed 
acceptable. Bloodless extracorporeal membrane oxy-
genation (ECMO) has also previously been utilised in 
an adolescent Witness patient.24 It is essential to dis-
cuss alternatives with each Witness patient to assess 
their position, including their right to refuse treat-
ment, especially in situations that would result in loss 
of life or limb. Discussions should be clearly docu-
mented in the notes. In emergency situations, most 
Witnesses carry a signed and witnessed advance deci-
sion card to express their wishes in emergencies, refus-
ing allogenic whole blood and blood components, and 
also autologous pre-donation. If no such card is pres-
ent, and the patient is known to be a Witness, every 
effort should be made to avoid the use of blood and 
blood products, but the ultimate decision rests with 
the clinician responsible for that patient.23 It is vital the 
clinician is adequately educated regarding the legal 
and ethical challenges which a Witness case presents in 
order to optimise patient management.
Legal and ethical challenges
The key ethical principles which underpin medical prac-
tice are non-maleficence, beneficence, autonomy and 
justice and their utilisation applies to care of any patient 
undergoing cardiac surgery, including Witnesses.11,12,23,25 
This is outlined, along with core legal principles, within 
existing clinical guidelines, as well as case reports, with 
one notable example by Papalexopoulou et al.12 This case 
helps to demonstrate the ethical principles of benefi-
cence and non-maleficence, as it presents a complex case 
in which the risk-to-benefit of treatment was vital to 
assess.12 It discusses that it can be deemed inappropriate 
for clinicians to refuse to treat a patient based on such 
factors as high risk.12 A clinicians choice to treat Witness 
patients is further noted in guidance by RCS England.23 
Doctors do have a choice about whether to treat patients 
who refuse blood transfusion, as the clinicians may deem 
this a conflict to their role as a doctor, especially in life-
saving situations. If so, the refusing clinician must refer 
the patient to a doctor who is prepared to perform treat-
ment with knowledge of the patients’ views. This must be 
recorded adequately to prevent claims of misconduct.23 
Furthermore, the concept of adequate note-taking and 
record keeping is also considered within guidelines with 
regards to discussions about treatment options and even-
tual decision making with patients, allowing for auton-
omy.10,23 Patients with mental capacity have the right to 
refuse treatment, and this is upheld in both ethical and 
legal respects, making administration of blood products 
against the patients will potentially unlawful.23 It is 
imperative that alternative treatments are made available 
to Witness patients, with a number having been devel-
oped over the years.
Alternatives to blood transfusion
The use of alternative treatments to blood transfusion is 
widely discussed within the clinical literature. It is espe-
cially noted within a number of case reports and case 
series specific to Witness patients. One such example is 
a case report by Robblee et  al.,26 which describes the 
novel use of prothrombin complex concentrate and 
cryoprecipitate in a Witness patient undergoing a redo 
aortic valve replacement and bypass graft. Additionally, 
many authors within the literature offer protocols from 
their own centres for the conservation of blood products 
and management of patients who refuse these pre, post 
and peri-operatively.17,27,28
In addition to these protocols, guidelines and recom-
mendations exist, produced by the National Institute of 
Health and Clinical Excellence (NICE), the Royal College 
of Surgeons of England and the Joint United Kingdom 
(UK) Blood Transfusion and Tissue Transplantation 
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Services Professional Advisory Committee.11,23,29 These 
provide further clarification on the alternatives to blood 
transfusions and the key information from these has 
been summarised in Table 1.
Novel therapies are being developed as further alter-
natives to blood transfusions, such as artificial blood 
substitutes. These include perfluorochemical-based 
substitutes, recombinant-Hb and the use of stem cells 
for the production of red blood cell alternatives. 
Although not currently approved for use in the UK, 
these provide an example of on-going developments in 
the subject area.30,31
One key factor, which is referenced frequently 
throughout the clinical literature and within guideline 
criteria, is the importance of discussion of various thera-
peutic options with the patient.10,11,23 This is in order to 
establish which therapy is most suitable for the patient, 
however, evidence of direct comparisons between thera-
pies in Witness patients appears to be lacking. One such 
example of a comparison comes from a study compar-
ing anti-fibrinolytics in 59 Witness patients (aprotinin, 
TXA and no anti-fibrinolytic use), which found that 
aprotinin reduced median drain output compared to 
TXA or no agent used (330 vs 500 vs 440 mL, respec-
tively), but that the agent used made no difference to 
mortality, morbidity or LOS.32 However, the study stated 
that due to possible bias within the selection of patients, 
these results were not fully conclusive.31 Aprotinin was 
removed from the market in 2008 and is now only uti-
lised in those with heavy bleeding.11,33
Overall, clinicians must establish the level of accept-
able use of blood products with the patient pre-opera-
tively and additionally discuss the risks of lack of use in 
emergency situations.5,10,11,23 Furthermore, the utilisa-
tion of a multidisciplinary team (MDT) approach is 
highlighted frequently within the literature as being 
central to the establishment of a bloodless protocol for 
Witness patients.34–36 This is especially important given 
Table 1. Alternatives to blood transfusion.
Category Therapies Utilisation in cardiac surgery Suitability for witness patients
Pharmacological • Tranexamic acid








Aprotinin was utilised in cardiac 
surgery before temporary withdrawal 
in 2008, and is now used in patients 
where high bleeding risk outweighs 
drug side effects, which include renal 
failure. Recombinant activated Factor 
VII is typically used to treat bleeding 
when Haemophilia A or B patients 
undergo surgery, but is also utilised 
off-label within cardiac surgery
Generally accepted but 




•  Cell salvage: intraopera-
tive and postoperative
•  Predeposit autologous 
donation
•  Normovolaemic haemo-
dilution
Intraoperative cell salvage with 
tranexamic acid is recommended for 
use in cardiac surgery by NICE, due 
to high anticipated blood loss. Acute 
normovolaemic haemodilution is 
commonly utilised in cardiac bypass 
surgery but includes risks of cardiac 
ischaemia and volume overload
Cell salvage and haemodilution 
can be classed as acceptable. 
Predeposit autologous dona-





•  Consider laparoscopic/
endoscopic/transcatheter 
approaches where  
applicable
•  Optimise vasoconstriction 
using medication, clamps 
and tourniquets as  
appropriate
•  Utilise regional anaesthe-
sia where appropriate
•  Utilise deliberate, con-
trolled hypotension and 
hypothermia
•  Utilise equipment such 
as harmonic scalpels and 
radiofrequency ablation 
techniques
The utilisation of minimal approaches 
has been advocated in cardiac surgery 
in recent years. One key example of 
this is the utilisation of transcatheter 
device closure as opposed to surgical 
closure of atrial and ventricular septal 
defects
Majority of these consider-
ations will be applicable as they 
do not utilise blood products 
specifically
Potential therapeutic options available and currently advocated as alternatives to blood transfusions as per current guidelines and recommendations.
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that blood transfusions themselves have associated risks 
and consequences, and that in some circumstances a 
bloodless regime may in fact be a good treatment 
approach.10,37
Blood transfusions and associated 
risks
Blood transfusions are not without risk, for example 
acute transfusion reactions, ranging from mild to life-
threatening, such as mild urticaria, acute haemolytic 
reactions, transfusion-associated circulatory overload 
and transfusion-related acute lung injury.38 In several 
cases, the risk is greater when transfusing blood prod-
ucts versus management without transfusion. Engoren 
et  al.39 found that even after comorbidities, age and 
additional confounding variables were accounted for, 
the 5-year mortality rate had increased by 70% in 
patients that received a blood transfusion compared to 
those who did not. Similarly, research including 10,289 
patients receiving blood transfusions demonstrated, 
after controlling factors such as demographics and 




It is important for both clinicians and service providers 
to assess whether they are adequately equipped to pro-
vide Witnesses patients with the best care.12 A number 
of complex cardiac surgery case reports demonstrate 
this and express the importance of referral to tertiary 
centres.12,28 This was especially noted in a case report by 
Papalexopoulou et  al.,12 where a Witness patient was 
eventually operated on for an aortic dissection following 
previous assessment at two other centres.
A further factor that could be assessed at the pre-
operative stage for Witness patients is the relative risk of 
patients requiring a blood transfusion during surgery. A 
number of tools have been developed to aid with this, 
such as the use of the ‘Transfusion Risk And Clinical 
Knowledge (TRACK) score’, which was utilised by Kim 
et al.41 for evaluating Witness patients, as well as the use 
of the ‘Transfusion Risk Understanding Scoring Tool 
(TRUST)’ utilised on Witness patients by Moraca et al.4
There are a number of other standard pre-operative 
steps which clinicians must undertake in order to appro-
priately manage Witness patients. One of the most 
important and frequently studied in the literature is the 
optimisation of pre-operative haemoglobin levels 
through the use of Erythropoietin (EPO) and either oral 
or IV iron.3,27,42–44 The use of EPO in particular was 
explored by Duce et  al.8 in a matched cohort study, 
which compared patients who were treated with EPO 
and declined blood transfusion, to controls who did not 
receive EPO at all. The study noted that there were no 
clinically significant differences in outcomes measured 
between the two cohorts, demonstrating the positive 
impact of EPO for patients refusing transfusion and 
hence supports its use for Witness patients.8
Eleven comparative studies discussing outcomes 
between Witnesses and non-Witnesses were 
found2,16,21,45–52 (Table 2) and these often gave agents to 
increase the preoperative Hb. This varied between stud-
ies and makes comparison more challenging. Six of the 
studies reported preoperative Hb levels,45–48,51,52 with 
three of these showing higher levels for the Witness 
group (Witness vs non-Witness: 13.7 vs 12.8 g/dL, 
p = 0.01;45 13.9 vs 12.3 g/dL, p < 0.0001;47 13.6 vs 12.9 g/
dL, p = 0.0148). Similar preoperative haemoglobin levels 
were reported in Witness only studies (12.1 ± 1.3,53 
13.91,8 14.131 and 14.5 g/dL54). Postoperative haemoglo-
bin levels were reported in five of the 11 comparative 
studies, with three showing a significantly higher result 
in the Witness group (Witness vs non-Witness: 10.8 vs 
9.9 g/dL, p = 0.003;45 11.7 vs 9.8 g/dL, p < 0.0001;47 11 vs 
10 g/dL, p = 0.00348). A non-comparative study reported 
a similar postoperative haemoglobin level in a Witness 
population (10.1 ± 1.5 g/dL).53 A study in Witnesses 
undergoing non-cardiac surgery found an increased risk 
of morbidity and mortality when haemoglobin levels 
were below 8 g/dL,55 with another study reporting simi-
lar outcomes within cardiac surgery,56 highlighting the 
importance of increasing Hb levels preoperatively.
Intra-operative
A number of intra-operative management techniques 
were noted previously in this paper in the section: 
Alternatives to Blood Transfusion. The predominant 
technique evident within the literature is intraoperative 
cell salvage due to its general acceptability with Witness 
patients.11,12,52,57 This is in addition to the use of intra-
operative normovolaemic haemodilution, which was 
utilised in 37 of the 45 Witness patients undergoing 
cardiac surgery in a study by McCartney et al.3
The utilisation of antifibrinolytics, heparinisation 
and carefully considered surgical techniques are also 
discussed within the clinical literature.3,11,58 An example 
of this is the use of sternum bone wax as standard for 
Witness patients in a study by Emmert et  al.59 Other 
operative aspects such as CPB and cross clamp times 
were not significantly different between Witness and 
non-Witness groups in various comparative studies 
(Table 2).
Another point noted from the literature is the impor-
tance of distinctions between adult and paediatric 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chambault et al. 7
series, such as that by Boettcher et al.,60 who reported on 
three Jehovah’s Witness infants undergoing cardiac sur-
gery. In this report, these patients were managed using a 
miniaturised extracorporeal circuit and increased crys-
talloid cardioplegia.60
Post-operative
Post-operative measures for Witness patients consists of 
standard post-operative cardiac care with additional 
considerations. From the literature, avoidance of hyper-
tension and the maintenance of normothermia is key, as 
is the use of paediatric or low-volume blood bottles for 
sample collection.27,53 Further to this, as can be expected, 
it is also important to continue the delivery of adjuncts 
such as IV iron and desmopressin as necessary to 
patients.27,53 Tanaka et  al.27 additionally suggests that 
Witness patients can be given haemodynamic support 
for longer in order to maximise systemic oxygen deliv-
ery. Mechanical ventilation is one such example of these 
measures, however, it has been noted in the literature 
that this is not a measure undertaken by all clinicians, as 
no difference was found in ventilation times in seven 
comparative studies between Witnesses vs controls 
(Table 2).2,45,48–52
Six of the 11 comparative studies in Table 2 which 
reported the outcome of blood loss did so differently, 
making direct comparison difficult.2,21,48,50–52 However, 
within the studies themselves, two found that the 
Witness group experienced significantly less postopera-
tive blood loss compared to the non-Witness control 
(Witness vs non-Witness: 466.8 vs 843 mL, p = 0.0001;45 
312 ± 141 vs 721 ± 619 mL, p < 0.0550). This may be 
explained by more careful surgery and the blood con-
serving strategies discussed in the studies. Binder et al.43 
investigated different transcatheter aortic valve replace-
ment (TAVR) techniques and concluded the use of 
transfemoral TAVR decreased blood loss when no 
transfusions were given. Taken together, the results sug-
gest that Witnesses do not have more postoperative 
blood loss than non-Witnesses, and may even have bet-
ter outcomes due to strategies employed.
Emergency situations
It is now considered relatively common to carry out 
uncomplicated elective cardiac surgery on Witnesses, as 
this enables meticulous planning and execution of blood 
management strategies. However, emergency cardiac 
surgery does not allow for careful planning, presenting a 
greater challenge and thus increasing the risk of bleed-
ing both peri- and post- operatively. Under such cir-
cumstances the doctor has a legal right to determine 
whether to proceed with a blood transfusion if they can-
not clearly ascertain the refusal of blood products.5 
Emergency cardiac surgery in Witnesses presents addi-
tional problems; presentation with severe anaemia and 
bleeding is inherently difficult to manage without the 
transfusion of blood. Viele and Weiskopf61 found that in 
Witnesses who did not receive transfusions, and had a 
haemoglobin of ⩽8 g/dL or a haematocrit of ⩽24%, 
there was a 37% mortality rate (50 of 134). This has 
since been supported by Hogervorst et  al. who high-
lighted an association between low haemoglobin levels 
(<8 g/dL) and levels of mortality and morbidity.56 
Contrary to this, a study carried out over a 10-year 
period on 91 Witnesses undergoing cardiac surgery 
found no significant difference in the risk of mortality 
or major complications between those who received 
emergency compared to elective surgery.53
It is important to note that differences in outcomes 
may arise during surgical complications where large 
amounts of blood are lost before the complication is 
resolved. This type of event is rare and so may not show 
in any study. This situation may become non-recovera-
ble for Witnesses, as the blood lost in unable to be 
replaced, or replaced adequately with alternatives if per-
mitted.
Jehovah’s Witnesses compared 
to non-Jehovah’s Witnesses: 
Outcomes in cardiac surgery
As mentioned previously, 11 studies were identified 
which compared outcomes for Witnesses and non-Wit-
nesses following cardiac surgery. Table 2 details the out-
comes for the comparative studies reviewed. Many other 
studies were identified that discussed the outcomes of 
cardiac surgery for Witnesses only, which will be dis-
cussed below.
Mortality
In-hospital mortality figures were given for 10 out of 
the 11 comparative studies found.2,16,21,45–52 None 
stated a significant difference in mortality rates 
between Witnesses and non-Witnesses. Witness in-
hospital mortality rate in the comparative studies 
varied between 0% and 18.8%. These figures are simi-
lar to those found in non-comparative studies, which 
ranged from 0% to 14.3%.8,17,32,44,53,54,58 One study by 
Ramiaramanana et  al.54 split the 153 Witness study 
population into low and high risk patients using their 
co-morbidities. Of the 13 classed as high risk, 3 died 
(23%), which was significantly higher than those in 
the low risk group (3 of 140 (2.1%), p = 0.001).54 Jassar 
et al.53 compared mortality rates in Witnesses under-
going elective versus urgent surgery, showing the 
mortality rate was higher in the elective surgery 
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group (5 vs 0, respectively), although the difference 
was not significant (p = 1.0). This study suggests 
urgent surgery can be carried out on Witnesses with 
low risk, despite no preoptimisation of Hb levels.
Thirty-day mortality was reported in a number of 
studies. Only three of the 11 comparative studies 
reported the data, but of the three studies, no difference 
in rates was found.45,47,50 Again, non-comparative stud-
ies found similar results (comparative: 0%–3.06%;45,47,50 
non-comparative 0%–5%4,17,44,58). Vaislic et al.17 reported 
a drop in 30-day mortality with time, stating 3% in those 
operated on between 1991 and 2003 and 1% for those 
between 2003 and 2012. They account for this by better 
techniques and optimisation preoperatively. A study by 
Ott and Cooley in 1977 found a 30-day mortality rate of 
9.4%,62 but this study was more than 40 years ago and 
also did not distinguish between outcomes for adults 
and children, which may account for the higher per-
centage seen.
Longer term survival rates were reported in few stud-
ies, with only one of the comparative studies sharing this 
outcome. Pattakos et al. reported survival estimates of 
Witnesses were 86%, 69%, 51% and 34% at 5, 10, 15 and 
20 years after surgery, respectively, vs 74%, 53%, 35% 
and 23% for non-Witnesses, showing Witnesses had 
better survival rates.16 Jassar et  al.53 stated the 1- and 
5-year survival rates for Witnesses after cardiac surgery 
to be 87.3% ± 3.4 and 76.1% ± 5.4, respectively. The 
5-year survival rates reported for those undergoing 
CABG only were reported to be 90.3%.
Morbidity
All studies found reported a different set of outcomes 
related to morbidity, making comparison for all stated 
difficult. The most commonly reported morbidity out-
comes for the comparative studies can be found in 
Table 2 and are discussed below. Overall, there appears 
to be no increased risk of morbidity among Witness 
patients.
Acute myocardial infarction and stroke. Eight out of 11 
comparative studies reported rates of myocardial infarc-
tion (MI) postoperatively. None of the studies found a 
difference in rates between the Witness and non-Wit-
ness groups, with results ranging from 0% to 6.3% and 
0% to 4.2%, respectively.2,16,45,48–52 The rates of MI in 
studies that included Witnesses only were similar, 0%8 
and 3%.58
Eight of the comparative studies also reported rates 
of postoperative stroke. Again, none of the studies found 
a difference between the two groups, with frequency 
ranging from 0% to 5.1% for both groups.2,16,45,48–52 
Non-comparative studies found low rates of stroke also 
(04, 1.1%53 and 3%58).
Acute kidney injury. Acute kidney injury (AKI) was men-
tioned as an outcome in nine out of the 11 comparative 
studies. The results are mixed, with several stating no 
difference in the rates of AKI seen between the two gro
ups,2,21,45–50 one study reporting a significant decrease in 
AKI in the non-Witness group51 and two studies show-
ing a significant decrease in AKI for Witnesses.16,52 The 
range of patients with postoperative AKI in the com-
parative studies was large (0%–73.3% for Witnesses and 
0%–77.8% for the non-Witness group). Two of the non-
comparative studies found varying rates of AKI among 
Witnesses, with one study reporting it in 2.5% of 
patients,4 whereas Duce et  al.,8 which compared out-
comes for Witnesses given EPO pre operatively to those 
not given EPO, found AKI rates to be 47.17% and 
41.51%, respectively. The wide difference in rates 
reported may be accounted for by the varying definition 
of AKI used and the vast array in type of surgeries car-
ried out in different studies, which makes it problematic 
to form any definitive conclusion concerning the risk of 
AKI in Witnesses following cardiac surgery.
Infection. Infection rates were not significantly different 
between the Witness and non-Witness groups in any of 
the six studies which reported this outcome.2,16,21,46,47,50 
Witness only studies reported varying infection rates of 
0,4 1.1%,53 3%58 and 9.43%.8 Sepsis was recorded for 
2.2% of patients in one study.53
Length of stay. Overall hospital length of stay (LOS) was 
reported for 10 out of 11 comparative stud-
ies,2,16,21,46,47,50–52 with three reporting a significantly 
decreased LOS for Witness patients compared to the 
non-Witness group (10.3 vs 13.4 days, p = 0.032;45 7.0 vs 
8.0 days, p < 0.00116 and 12.2 vs 17.3 days, p = 0.05,48 
respectively). Studies which only described outcomes 
for Witnesses stated similar LOS times ranging from 5,8 
8.1 ± 4.8,4 9.83 ± 7.9253 and 12.81 ± 6.5844 days.
Seven of the 11 studies mentioned ICU LOS 
times,2,16,45,46,48–50 with one study finding a difference 
was between the two groups (Witness vs non-Witness: 
25 vs 48 h, p < 0.00116). Non-comparative studies were 
found to state a wide range of ICU LOS times, ranging 
from 24 to 103.68 ± 92.64 h.4,44,58 Duce et al.8 found that 
Witnesses not given EPO preoperatively were less likely 
to remain in ICU for more than 24 h and Ramiaramanana 
et al.54 saw a significant difference in LOS for Witnesses 
classified as low vs high risk (68.4 vs 156 h, respectively 
(p = 0.01)). The difference in results may be again due to 
the vast array of different surgeries and techniques used 
in the studies.
Reoperation for bleeding. One comparative study found 
that Witnesses were less likely to need reoperation for 
bleeding than the control group (3.7% vs 7.5%, p = 0.01, 
Chambault et al. 9
respectively16). The other 6 studies that compared the 
two groups found no difference in this outcome.45,48–52 
Five non-comparative studies found the following per-
centages of patients requiring reoperation for bleeding: 
0,44 2.2,53 5,4 1058 and 11.4%.54 Again, the different sur-
geries in the studies may account for the differences, but 
the results suggest a low risk of reoperation for bleeding 
in the Witness population.
Quality of life. One study reviewed compared quality of 
life outcomes following cardiac surgery between 14 
Witnesses and 18 non-Witness controls. The authors 
employed the MacNew questionnaire, which showed 
no difference in physical (p = 0.54), emotional (p = 0.12), 
social (p = 0.21) and global (p = 0.25) scores between the 
two populations.63
Limitations and future research
There are several predominant limitations across the 
studies discussed in this review. Firstly, retrospective 
studies populate this area of research and are prone to 
selection bias as higher-risk Witnesses are more likely 
to be excluded, therefore studies will not accurately 
reflect all those in need of surgery. Additionally, a large 
proportion of the study designs are single-centre and 
nonrandomised.3,8,57 There is an increased likelihood 
that surgeons will be more cautious when operating on 
Witnesses, this in turn could result in reduced blood 
loss, which is impossible to measure and thus cannot 
be accounted for.56 However, it is important to note 
that these research limitations were taken into account 
and propensity matching employed in some studies, to 
define the control group and minimise such limita-
tions.15,57 Nonetheless, this only accounts for variables 
that were recorded, when in reality there will have 
been a greater number of confounding variables that 
could not be included in the propensity matching.
Only one study mentioned cost comparisons for 
treatment between the two groups and found no signifi-
cant difference in total costs for Witnesses and their 
controls.47 More research is needed in this area.
Finally, a large proportion of the research discussed 
in this review consisted of either very small sample 
sizes2 or included case reports and are therefore subject 
to all recognised limitations, including retrospective 
limitations aforementioned, generalisability, causality, 
information and publication bias, overinterpretation or 
misinterpretation of data. Future research is needed to 
provide greater clarity on the outcomes of cardiac sur-
gery in Witnesses that refuse blood products. There 
needs to be an increased focus on multi-institutional 
studies with a greater number of participants to validate 
the research to date,8,63 along with readmission rates and 
long term mortality following discharge,2 and a more in 
depth cost analysis of pre-, intra-, and post-operative 
optimisation of witnesses during cardiac surgery.8
Conclusion
Jehovah’s Witness patients undergoing cardiac surgery 
present a unique challenge for clinicians. Good com-
munication with the patient and an MDT approach is 
required in order to ensure safe and successful treat-
ment. Overall, within the clinical literature, the use of a 
bloodless protocol for these patients does not appear to 
significantly impact upon clinical outcomes when com-
pared to non-Witness patients, and it has even been 
suggested that a bloodless approach could provide 
advantages to all patients undergoing cardiac surgery. 
However, further research into the long term outcomes 
of these patients, especially in larger cohorts and across 
multiple centres, is still required.
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